By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Mitomics today announced that it has signed a non-exclusive agreement with LabMD to market its Prostate Core Mitomic Test in the US.

The PCM test is based on mitochondrial DNA and identifies a biomarker that indicates the presence of cancerous cells in prostate biopsy tissue. Thunder Bay, Ontario-based Mitomics said the test has a sensitivity of 84 percent with a negative predictive value of 91 percent.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Five researchers are to share this year's Albany Medical Center Prize for their work on the CRISPR/Cas9 gene-editing tool, the AP reports.

Stat News reports on how white supremacists cope with surprising genetic ancestry testing results.

In Genome Research this week: sex-biased gene expression evolution in malaria mosquitos, method to find ancient selective sweeps, and more.

Iceland has nearly eliminated Down syndrome from its population, CBS News reports.